Latham & Watkins Advises Perrigo on Proposed Divestiture of Dermacosmetics Business

Latham & Watkins LLP has advised Perrigo Company plc, a leading global provider of consumer self-care products, on its proposed divestiture of its dermacosmetics branded business to Kairos Bidco AB, an investment vehicle managed by global investment firm KKR. The transaction is subject to customary conditions and regulatory approvals, with closing expected in the first quarter of 2026.

This strategic divestiture supports Perrigo’s “Three-S” plan to stabilize, streamline, and strengthen its portfolio, allowing Perrigo to focus on high-growth, high-return opportunities. Brands within this proposed transaction include ACO, Biodermal, Emolium, and Iwostin.

The Latham team was led by Düsseldorf corporate partner Ingo Strauss and Hamburg Healthcare & Life Sciences partner Christoph Engeler, with Paris partner Eveline Van Keymeulen, and associates Henrietta Ditzen, Sönke Bock, and Antanas Grimalauskas. Advice was also provided on IP matters by Frankfurt partner Susan Kempe-Müller, with associate Johannes Huschka; on tax matters by Hamburg partner Tobias Klass, with associate Johannes Lieb; on antitrust matters by Frankfurt partner Max Hauser, with associate Judith Jacop; on FDI matters by Hamburg partner Jana Dammann de Chapto; and on data privacy matters by Frankfurt counsel Wolf-Tassilo Böhm.